CoChat

Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma

Open access
Plesner, Torben, Arkenau, Hendrik-Tobias, Gimsing, Peter, Krejcik, Jakub, Lemech, Charlotte, Minnema, Monique C., Lassen, Ulrik, Laubach, Jacob P., Palumbo, Antonio, Lisby, Steen, Basse, Linda, Wang, Jianping, Sasser, A. Kate, Guckert, Mary E., de Boer, Carla, Khokhar, Nushmia Z., Yeh, Howard, Clemens, Pamela L., Ahmadi, Tahamtan, Lokhorst, Henk M., Richardson, Paul G. · 2016 · Blood
Cited by 109

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Key Points: Daratumumab plus lenalidomide/dexamethasone elicited an overall response rate of 81% (63% very good partial response or better). Adverse events were manageable and in accord with the individual toxicity profiles of daratumumab and lenalidomide/dexamethasone.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1182/blood-2016-07-726729

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 14

  1. Meadows, 2013, Management of double-refractory multiple myeloma., Curr Hematol Malig Rep, 8, 253, 10.1007/s11899-013-0173-2 · DOI
  2. Laubach, 2014, Current strategies for treatment of relapsed/refractory multiple myeloma., Expert Rev Hematol, 7, 97, 10.1586/17474086.2014.882764 · DOI · Paper page
  3. Lin, 2004, Flow cytometric immunophenotypic analysis of 306 cases of multiple myeloma., Am J Clin Pathol, 121, 482, 10.1309/74R4TB90BUWH27JX · doi:10.1309/74r4tb90buwh27jx · Paper page
  4. Santonocito, 2004, Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiple myeloma patients., Leuk Res, 28, 469, 10.1016/j.leukres.2003.09.015 · DOI
  5. Krejcik, 2016, Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma., Blood, 128, 384, 10.1182/blood-2015-12-687749 · DOI · Paper page
  6. van der Veer, 2011, Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab., Haematologica, 96, 284, 10.3324/haematol.2010.030759 · DOI · Paper page
  7. Mateos, 2015, An open-label, multicenter, phase 1b study of daratumumab in combination with pomalidomide-dexamethasone and with backbone regimens in patients with multiple myeloma [abstract]., Haematologica, 100, 84
  8. McCudden, 2016, Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference., Clin Chem Lab Med, 54, 1095, 10.1515/cclm-2015-1031 · DOI · Paper page
  9. Xu, 2015, Understanding the dose regimen for daratumumab in patients with relapsed or refractory multiple myeloma (MM) after prior proteasome inhibitors (PIs) and immunomodulatory drugs (IMiDs): a quantitative pharmacologic perspective [abstract]., Blood, 10.1182/blood.V126.23.4254.4254 · doi:10.1182/blood.v126.23.4254.4254
  10. Dimopoulos, 2009, Long-term follow-up on overall survival from the MM-009 and MM-010 phase III trials of lenalidomide plus dexamethasone in patients with relapsed or refractory multiple myeloma., Leukemia, 23, 2147, 10.1038/leu.2009.147 · DOI · Paper page
  11. Chari, 2015, Outcomes and management of red blood cell transfusions in mutliple myeloma patients treated with daratumumab [abstract]., Blood, 126, 10.1182/blood.V126.23.3571.3571 · doi:10.1182/blood.v126.23.3571.3571
  12. De Vooght, New mAb therapies in multiple myeloma: interference with blood transfusion compatibility testing [published online ahead of print 6 July 2016]., Curr Opin Hematol
  13. van der Veer, Improved myeloma targeting by combination of the human anti-CD38 antibody daratumumab with lenalidomide and bortezomib [abstract]., Blood
  14. van der Veer, 2011, The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies., Blood Cancer J, 1, e41, 10.1038/bcj.2011.42 · DOI · Paper page

Cited by

See all 109

Metadata

Authors
Plesner, T., Arkenau, H.-T., Gimsing, P., Krejcik, J., Lemech, C., Minnema, M. C., Lassen, U., Laubach, J. P., Palumbo, A., Lisby, S., Basse, L., Wang, J., Sasser, A. K., Guckert, M. E., de Boer, C., Khokhar, N. Z., Yeh, H., Clemens, P. L., Ahmadi, T., Lokhorst, H. M., & Richardson, P. G.
Venue
Blood
Published
2016-10-06
Volume
128
Issue
14
Pages
1821-1828
ISSN
  • 0006-4971 (ISSN-L)
  • 1528-0020
OpenAlex
W2510398184
Cited by
109
References
14
FWCI
17.64
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. https://app.cochat.ai/papers/10.1182/blood-2016-07-726729
The paper
Plesner, T., Arkenau, H.-T., Gimsing, P., Krejcik, J., Lemech, C., Minnema, M. C., Lassen, U., Laubach, J. P., Palumbo, A., Lisby, S., Basse, L., Wang, J., Sasser, A. K., Guckert, M. E., de Boer, C., Khokhar, N. Z., Yeh, H., Clemens, P. L., Ahmadi, T., . . . Richardson, P. G. (2016). Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood. https://doi.org/10.1182/blood-2016-07-726729

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.